You are here

  • Home
  • Archive
  • Volume 9, Issue 6
  • Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma

 

Online download statistics by month:

Online download statistics by month: June 2021 to August 2023

AbstractFullPdf
Jun 2021206206115
Jul 2021534534317
Aug 2021330330109
Sep 202121121173
Oct 2021247247103
Nov 202118518487
Dec 202120120168
Jan 202221621966
Feb 202250250376
Mar 2022382385103
Apr 202224225198
May 2022182187105
Jun 2022151161103
Jul 2022144147112
Aug 202212913266
Sep 202215215984
Oct 202213813979
Nov 202214714774
Dec 202213313351
Jan 202321922066
Feb 202336836891
Mar 202323623888
Apr 202326526574
May 202381481573
Jun 202378278269
Jul 202367767759
Aug 202375675750
Total854985982459